**Agentic reinforcement learning controllers trained via Hamiltonian-based policies (risk-reward optimization) will modulate junctional tension fluctuations in confluent epithelial monolayers to induce persistent Brownian motion regimes that resist jamming transitions, measurable via single-cell tracking.**
Adversarial Debate Score
55% survival rate under critique
Expert panel critique
Independent views, each critiquing the hypothesis on its own — the score rewards genuine disagreement and discounts consensus.
Supporting Research Papers
- Residual RL--MPC for Robust Microrobotic Cell Pushing Under Time-Varying Flow
Contact-rich micromanipulation in microfluidic flow is challenging because small disturbances can break pushing contact and induce large lateral drift. We study planar cell pushing with a magnetic rol...
- Universal Persistent Brownian Motions in Confluent Tissues
Biological tissues are active materials whose non-equilibrium dynamics emerge from distinct cellular force-generating mechanisms. Using a two-dimensional active foam model, we compare the effects of t...
- Controlling inertial active Brownian motion via stochastic resetting
Inertia is intrinsic to many living and synthetic active systems, from animals and robotic agents to colloidal swimmers, and it strongly shapes transport. Many such systems employ intermittent restart...
Computational Result
An LLM's reading of the literature — not computational verification.
Epithelial dynamics and reinforcement learning show potential but lack definitive evidence.
Method: literature_meta · Result: inconclusive · Confidence: 60%
Formal Verification
Z3 checks whether the hypothesis is internally consistent, not whether it is empirically true.
This discovery has a Claude-generated validation package with a full experimental design.
Precise Hypothesis
An agentic reinforcement learning (RL) controller — trained with a Hamiltonian-based policy that jointly optimizes a "risk" term (variance/uncertainty of junctional tension) and a "reward" term (maintenance of target tension setpoints or motility metrics) — when coupled in closed loop to a vertex-model or cell-based simulation (and, in the extended version, to optogenetic actuation of junctional myosin in a real epithelial monolayer), will produce a statistically significant increase in the fraction of cells exhibiting mean-squared-displacement (MSD) exponents α > 1.4 (persistent/super-diffusive regime) over a 2-hour window, and will suppress the fraction of cells with caged/sub-diffusive trajectories (α < 0.3) relative to (a) an untrained/random-policy controller and (b) a standard scalar-reward RL controller (no Hamiltonian risk term), at fixed mean tension and fixed cell density (confluency ≥ 0.95). The effect must be reproducible across ≥3 independent simulation seeds / monolayer replicates with effect size Cohen's d ≥ 0.5.
- No significant difference (p > 0.05, permutation test, FDR-corrected) in MSD exponent distributions between Hamiltonian-RL-controlled and random/scalar-reward-controlled monolayers across ≥3 replicates.
- Effect size Cohen's d < 0.2 for the primary endpoint (fraction of cells with α > 1.4).
- Controller achieves reward/risk objective in training (converges) but produces no measurable change in downstream jamming/unjamming statistics (energy barrier, four-point susceptibility χ4, cage-relative displacement).
- Effect present only in simulation but absent (null or reversed) in optogenetic in vitro replication with matched actuation bounds.
- Effect attributable entirely to mean tension shift (confounded), i.e., disappears after controlling for mean junctional tension via ANCOVA.
Spine & Adversarial Read
- highThe 'Hamiltonian' framing may be cosmetic — a well-tuned scalar-reward PPO with an entropy bonus could achieve the same variance-regularized exploration effect without any formal risk-reward duality, making the mechanistic novelty claim unfalsifiable as stated.Protocol includes matched-compute scalar-reward baseline as the key control; however, EVP does not yet specify an ablation isolating the costate/dual-ascent mechanism itself (e.g., fixed-lambda vs adaptive-lambda variant) — this ablation should be added before claiming the Hamiltonian structure specifically (not just risk regularization generally) is responsible for the effect.
- mediumWhy vertex-model/SPV simulation and optogenetic RhoA actuation specifically, rather than e.g. traction-force-based control, substrate stiffness modulation, or a continuum active-nematic model — the methodology choice is not justified against alternatives with potentially higher biological fidelity or lower cost.Vertex/SPV models are chosen because they are the standard, validated framework for the jamming transition (shape-index criterion) in this literature, giving direct comparability to prior benchmarks; optoGEF-RhoA is chosen because it is the most established junctional-tension optogenetic actuator with published dose-response calibration. This justification is asserted here but not empirically defended in the EVP against alternative actuation modalities — a real gap.
- mediumConfluent monolayer jamming/unjamming may be dominated by biochemical (EMT-like, cell-autonomous) programs rather than purely mechanical junctional tension, so an external tension controller may have limited authority over the true jamming order parameter regardless of policy sophistication.Explicitly flagged in EXTERNAL_CONFLICTS; the EVP's Phase 2 in vitro gate is designed to catch this failure mode, but no experiment here directly measures the relative contribution of biochemical vs. mechanical control, so this remains an acknowledged, unresolved limitation rather than a solved problem.
Experimental Protocol
Phase 1 (in silico, primary): Self-propelled Voronoi (SPV) or vertex-model confluent monolayer (N=400–1000 cells, periodic boundary), tension-fluctuation actuation exposed as an RL action space. Train 3 controller variants: (i) random policy, (ii) scalar-reward PPO baseline, (iii) Hamiltonian risk-reward policy (custom actor-critic with Pontryagin-inspired costate/risk regularization). Run closed-loop control for simulated 2-hour windows, track all cell centroids at 1-frame/30s. Repeat ×10 seeds per condition.
Phase 2 (in vitro, confirmatory, optional/staged): MDCK monolayer expressing optoGEF-RhoA at junctions + membrane/nuclear marker for tracking. Blue-light patterned stimulation driven by the same trained policy (ported via a real-time image-analysis-to-actuation loop). Track single-cell trajectories via Bayesian multi-object tracking for 2h, N≥3 biological replicates, ≥300 cells/replicate analyzed.
- Synthetic training corpus: vertex-model/SPV simulation trajectories (self-generated, ~10^4 episodes) with junctional tension, cell shape index, and centroid position logs.
- Benchmark unjamming datasets for calibration: existing published MSD/α and shape-index datasets from confluent monolayer jamming literature (e.g., Bi et al. SPV model reference trajectories) used to validate simulator fidelity before RL training.
- Optogenetic actuation calibration dataset: dose-response curves of optoGEF-RhoA light intensity vs. junctional tension (from literature or a dedicated calibration experiment, ~1 week).
- Cell tracking ground truth: manually annotated subset (≥50 cells × 5 frames) for tracker validation (precision/recall ≥0.95 required).
- Compute environment: differentiable/non-differentiable vertex-model simulator (e.g., modified
VoronoiCells.jl,PyVoro-based custom code, or CellGPU) integrated with an RL framework (Stable-Baselines3 / RLlib) via Gym-style environment wrapper.
- Primary: Hamiltonian-RL condition shows ≥1.3× the fraction of super-diffusive cells (α>1.4) vs. scalar-reward baseline, p<0.01 (FDR-corrected across seeds), Cohen's d≥0.5.
- Secondary: χ4 peak height reduced by ≥20% (less caging/heterogeneity) in Hamiltonian-RL vs. baseline.
- Confound check passes: effect survives ANCOVA controlling for mean tension (partial η²≥0.1 for condition after control).
- Robustness: effect replicates in ≥8/10 seeds directionally, ≥3/10 seeds at p<0.05 individually (meta-analytic combination significant).
- (If Phase 2 run) In vitro effect direction matches simulation with d≥0.3.
- Primary endpoint not met (d<0.2 or p>0.05 after FDR correction).
- Effect fully explained by mean tension shift (disappears under ANCOVA).
- Hamiltonian controller fails to converge / risk term dominates and collapses action space (degenerate policy, e.g., zero actuation).
- In vitro replication contradicts simulation direction with matched confidence (d<-0.3, i.e., reversed effect).
ROI Projection
Direct: licensing potential for closed-loop optogenetic bioreactor control software (tissue engineering, organ-on-chip QC). Indirect: platform reusable for any actuatable multicellular system (cardiac tissue rhythm control, epithelial barrier repair, tumor invasion suppression via forced jamming). Near-term commercial applicability moderate (3–5 yrs to product); near-term IP value high (novel control algorithm + closed-loop protocol).
TIME_TO_RESULT_DAYS: 120
Implementation Sketch
# Environment class MonolayerEnv(gym.Env): def __init__(self, vertex_model, n_cells=600): self.sim = vertex_model self.action_space = Box(low=0.5, high=2.5, shape=(n_edges,)) self.observation_space = Dict(tension=Box(...), shape_index=Box(...), topology=Graph(...)) def step(self, action): self.sim.apply_tension_modulation(action) self.sim.advance(dt) obs = self.sim.get_state() reward, risk = compute_reward_risk(obs, self.history) return obs, reward, risk, done, info # Hamiltonian actor-critic H = R(s,a) - lambda_t * Risk(s,a) policy_grad = grad(H, theta) lambda_t += eta * (Risk(s,a) - risk_budget) # dual ascent on costate # Training loop for episode in range(N_EPISODES): s = env.reset() for t in range(T): a = policy(s) s2, r, risk, done, _ = env.step(a) buffer.store(s,a,r,risk,s2) s = s2 update_actor_critic(buffer, H) update_lambda(buffer, risk_budget) # Analysis msd = compute_msd(trajectories, tau_range) alpha = fit_power_law(msd) chi4 = dynamic_susceptibility(trajectories) stats = mixed_effects_model(alpha ~ condition + (1|seed))
- Day 10: simulator fails to reproduce published jamming benchmark curves (R²<0.8) → abort/rebuild simulator before proceeding.
- Day 30: Hamiltonian policy fails to converge (reward/risk not stabilizing after 2× expected training steps) → revisit formulation before running full comparison.
- Day 45: pilot run (n=3 seeds) shows d<0.1 for primary endpoint → stop before committing full 10-seed/phase-2 budget.
- Day 90 (pre-Phase 2 gate): simulation results not significant or fail confound check → do not proceed to costly in vitro optogenetic phase.
NAMED_EXPERTS: []
CLOSEST_EXISTING_WORK: []
NOVELTY_NARROWING_REQUIRED: false
SPINE_STATEMENT: This hypothesis tests whether a Hamiltonian risk-reward RL controller modulating junctional tension can causally shift confluent epithelial monolayers toward a persistent, super-diffusive (anti-jamming) motility regime relative to non-Hamiltonian control baselines.